Anileridine

Anileridine (trade name: Leritine) is a synthetic analgesic drug and is a member of the piperidine class of analgesic agents developed by Merck & Co. in the 1950s.[1] It differs from pethidine (meperidine) in that the N-methyl group of meperidine is replaced by an N-aminophenethyl group, which increases its analgesic activity.

Anileridine
Clinical data
AHFS/Drugs.comMonograph
Routes of
administration		Tablets, injection
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding> 95%
MetabolismHepatic
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H28N2O2
Molar mass352.478 g·mol−1
3D model (JSmol)
Melting point83 °C (181 °F)
 NY (what is this?)  (verify)

Anileridine is no longer manufactured in the US or Canada.[2] Anileridine is in Schedule II of the Controlled Substances Act 1970 of the United States as ACSCN 9020 with a zero aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.83 for the dihydrochloride and 0.73 for the phosphate [3] It is also under international control per UN treaties.

Administration

As tablets or injection.[4]

Pharmacokinetics

Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2–3 hours.[5] It is mostly metabolized by the liver.

References
  1. U.S. Patent 2,897,204
  2. "Discontinued Prescription Drug Products". Canadian Pharmacists' Association. Archived from the original on 19 September 2008. Retrieved 28 July 2008.
  3. http://www.deadiversion.usdoj.gov/fed_regs/quotas/2014/fr0825.htm
  4. "Pharmaceutical Information - LERITINE". RxMed. Retrieved 16 June 2010.
  5. "Anileridine Consumer Information". MedicineNet. Retrieved 28 July 2008.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.